Collegium Pharmaceutical Inc (COLL) Actualités

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Collegium to Report Fourth Quarter and Full-Year 2024 Financial Results on February 27, 2025

STOUGHTON, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today...

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 3 - Initial statement of beneficial ownership of securities

Form 8-K - Current report

Collegium Appoints Nancy S. Lurker to its Board of Directors

STOUGHTON, Mass., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today...

Form 4 - Statement of changes in beneficial ownership of securities

Form 144 - Report of proposed sale of securities

Form 8-K - Current report

Collegium Provides 2025 Financial Guidance and Business Update

– Product Revenues, Net Expected in the Range of $735 Million to $750 Million – – Jornay PM® Net Revenue...

Form 4 - Statement of changes in beneficial ownership of securities